Skip to main content
    L

    Lineage Cell Therapeutics Inc (LCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.80
    -0.11 (-12.45%)

    Market Cap: $231.35M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Lineage Cell Therapeutics Inc (LCTX) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Lineage Cell Therapeutics (LCTX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Lineage Cell Therapeutics reported EPS of -$0.03, below the -$0.02 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -27.39%

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range-$0.04 - $0.08
    9 analysts
    Revenue Consensus
    $4.21M
    RangeN/A
    9 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.03
    Range-$0.03 - -$0.03
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.030.0%
    60d ago-$0.03-12.4%
    30d ago-$0.03-12.4%
    7d ago-$0.03-12.4%
    Current-$0.03
    Revenue Consensus
    $1.51M
    Range$1.07M - $2.41M
    4 analysts

    Next Report

    LCTX has an expected report date of Mar 3, 2027.

    LCTX Earnings Call

    The latest LCTX earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, LCTX beat 21, missed 14 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $1.43M, down 61.1% from $3.68M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.03-$0.02N/A-50.00%MissN/A40 up, 1 downNov 12, 2026$1.43M
    Jun 30, 2026-$0.03-$0.03-$0.04 - -$0.020.00%In lineN/A40 up, 1 downAug 6, 2026$1.07M
    Mar 31, 2026-$0.03-$0.02-$0.03 - -$0.02-36.50%MissN/A30 up, 1 downMay 12, 2026$1.73M
    Dec 31, 2025$0.00-$0.04-$0.14 - -$0.02+108.75%BeatN/A60 up, 0 downMar 5, 2026$6.61M
    Sep 30, 2025-$0.13-$0.03-$0.04 - -$0.02-333.33%MissN/A61 up, 2 downNov 6, 2025$3.68M
    Jun 30, 2025-$0.13-$0.03-$0.04 - -$0.02-333.33%MissN/A61 up, 0 downAug 12, 2025$2.77M
    Mar 31, 2025-$0.02-$0.03-$0.04 - -$0.02+33.33%BeatN/A52 up, 0 downMay 13, 2025$1.50M
    Dec 31, 2024-$0.01-$0.03-$0.04 - -$0.02+66.67%BeatN/A41 up, 0 downMar 10, 2025$2.87M
    Sep 30, 2024-$0.02-$0.03-$0.04 - -$0.03+33.33%BeatN/A30 up, 0 downNov 14, 2024$3.78M
    Jun 30, 2024-$0.03-$0.04-$0.05 - -$0.04+25.00%BeatN/A50 up, 0 downAug 8, 2024$1.41M
    Mar 31, 2024-$0.04-$0.04-$0.05 - -$0.020.00%In lineN/A60 up, 0 downMay 9, 2024$1.44M
    Dec 31, 2023-$0.03-$0.04-$0.09 - $0.00+25.00%BeatN/A70 up, 1 downMar 7, 2024$2.09M
    Sep 30, 2023-$0.04-$0.03-$0.07 - -$0.03-33.33%MissN/A70 up, 0 downNov 9, 2023$1.25M
    Jun 30, 2023-$0.03-$0.04-$0.07 - -$0.03+25.00%BeatN/A70 up, 0 downAug 10, 2023$3.23M
    Mar 31, 2023-$0.03-$0.05-$0.07 - -$0.03+40.00%BeatN/A60 up, 0 downMay 11, 2023$2.39M
    Dec 31, 2022-$0.03-$0.04-$0.05 - -$0.03+25.00%BeatN/A70 up, 0 downMar 9, 2023$1.92M
    Sep 30, 2022-$0.03-$0.04-$0.06 - -$0.02+25.00%BeatN/A80 up, 0 downNov 10, 2022$3.00M
    Jun 30, 2022-$0.04-$0.02-$0.11 - -$0.01-100.00%MissN/A70 up, 0 downAug 11, 2022$4.55M
    Mar 31, 2022-$0.04-$0.06-$0.10 - $0.08+33.33%BeatN/A50 up, 0 downMay 12, 2022$5.24M
    Dec 31, 2021-$0.17-$0.05-$0.06 - -$0.03-240.00%Miss-1800.0%60 up, 0 downMar 10, 2022$1.17M
    Sep 30, 2021-$0.03-$0.05-$0.06 - -$0.04+40.00%BeatN/A5N/ANov 10, 2021$2.27M
    Jun 30, 2021-$0.04-$0.04-$0.04 - -$0.030.00%In lineN/A3N/AAug 12, 2021$512000
    Mar 31, 2021-$0.05-$0.04-$0.05 - -$0.03-25.00%MissN/A3N/AMay 13, 2021$391000
    Dec 31, 2020$0.01-$0.05-$0.06 - -$0.04+120.00%BeatN/A5N/AMar 11, 2021$166000
    Sep 30, 2020-$0.04-$0.04-$0.05 - -$0.040.00%In lineN/A2N/ANov 4, 2020$571000
    Jun 30, 2020-$0.03-$0.05-$0.05 - -$0.03+40.00%BeatN/A4N/AAug 6, 2020$386000
    Mar 31, 2020-$0.06-$0.03-$0.09 - -$0.03-100.00%MissN/A5N/AMay 7, 2020$166000
    Dec 31, 2019-$0.03-$0.05-$0.07 - -$0.02+40.00%BeatN/A5N/AMar 12, 2020$1.24M
    Sep 30, 2019-$0.05-$0.05-$0.06 - -$0.050.00%In lineN/A3N/ANov 12, 2019$567000
    Jun 30, 2019-$0.06-$0.05N/A-20.00%MissN/AN/AN/AAug 8, 2019$779000
    Mar 31, 2019-$0.05-$0.06N/A+16.67%BeatN/AN/AN/AMay 9, 2019$928000
    Dec 31, 2018-$0.32-$0.07N/A-357.14%MissN/AN/AN/AMar 14, 2019$758000
    Sep 30, 2018-$0.08-$0.06N/A-33.33%Miss-125.8%N/AN/ANov 8, 2018$982000
    Jun 30, 2018-$0.07-$0.09N/A+22.22%BeatN/AN/AN/AAug 2, 2018$2.55M
    Mar 31, 2018-$0.10-$0.07N/A-42.86%MissN/AN/AN/AMay 10, 2018$701000
    Dec 31, 2017-$0.58-$0.07N/A-728.57%MissN/AN/AN/AMar 15, 2018$999000
    Sep 30, 2017$0.31-$0.08N/A+487.50%Beat+3.3%N/AN/ANov 9, 2017$1.69M
    Jun 30, 2017-$0.05-$0.09N/A+44.44%Beat-119.2%N/AN/AAug 2, 2017$381000
    Mar 31, 2017-$0.07-$0.09N/A+22.22%BeatN/AN/AN/AMay 10, 2017$390000
    Dec 31, 2016-$0.05-$0.14N/A+64.29%BeatN/AN/AN/AMar 16, 2017$1.08M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.28, after -$0.10 the year before. It was $0.32 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.28N/A
    Dec 31, 2024-$0.10N/A
    Dec 31, 2023-$0.13N/A
    Dec 31, 2022-$0.14N/A
    Dec 31, 2021-$0.29N/A
    Dec 31, 2020-$0.12N/A
    Dec 31, 2019-$0.19N/A
    Dec 31, 2018-$0.57N/A
    Dec 31, 2017-$0.39-221.9%
    Dec 31, 2016$0.32N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 7,900 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20267,9408
    2025Q4Dec 31, 20258,2569
    2025Q3Sep 30, 20258,30910
    2025Q2Jun 30, 20257,3259
    2025Q1Mar 31, 20257,2559
    2024Q3Sep 30, 20249,17311

    2026Q1 Earnings Call

    Opening remarks

    Ioana C. Hone Head of Investor Relations Thank you, Demi. Good afternoon, and thank you for joining us. A press release reporting our first quarter 2026 financial results was issued earlier today, 05/12/2026, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements. For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statements sections in today's press release and in the company's SEC filings including its most recent annual report on Form 10 and in the Form 10-Q filed today. We caution you not to place undue reliance on any forward-looking statements which speak only as of today, and are qualified by the cautionary statements and risk factors described in our SEC filings. With us today are Brian Culley, our Chief Executive Officer, and Jill Ann Howe, our Chief Financial Officer. I will now hand the call over to Brian.

    Brian Culley Chief Executive Officer Thank you, Ioana, and good afternoon, everyone. We appreciate you taking the time to join us today. We have a lot of great things to cover. I am going to try and keep it short so that we can have plenty of time for analyst questions. I do want to highlight the successful expansion of AlloSCOPE, our proprietary cell manufacturing platform, most notably because it led to the launch of COR1, our new wholly owned corneal endothelial cell transplant program. We also successfully met our first internal milestone with our ILT1 manufacturing initiative and established a new scientific advisory board and attracted a recognized, established cell therapy executive as its founding member. But before I share those and other updates, I will begin with the status of our lead clinical program, OpRegen. Data we reported several years ago from the OpRegen Phase 1/2a clinical study included improved anatomy of the retina, halting or reversal of atrophic progression, and improved vision in patients with dry AMD. These are compelling data because they are not known to occur naturally in human beings. Since we made these initial reports, two additional and very important advancements have occurred in the field. The first of these is that three other companies have reported similar results with their own version of an RPE transplant, independently providing further evidence in support of the mechanism and its treatment effects.

    Frequently Asked Questions About LCTX

    When is Lineage Cell Therapeutics's next earnings date?

    Lineage Cell Therapeutics's next earnings report is expected for Mar 3, 2027.

    Did LCTX beat earnings estimates last quarter?

    No. Lineage Cell Therapeutics reported EPS of -$0.03 for the quarter ended Sep 30, 2026, below the -$0.02 estimate by 50.00%.

    What EPS do analysts expect from LCTX next quarter?

    The consensus EPS estimate for Lineage Cell Therapeutics for the quarter ending Dec 31, 2026 is $0.00 from 9 analysts, with estimates from -$0.04 to $0.08.

    How often does LCTX beat earnings estimates?

    Lineage Cell Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -68.05%.